ArticleFrontiers in immunology2026

Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy.

Xiaoshi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.